Macular Degeneration Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older (male or female) who need cataract surgery with no other surgical procedures performed at the same time
• People who agree not to have any other eye surgery in either eye within 15 days before the study treatment starts, or at any point during the study
• People whose best vision with glasses or contact lenses is at least 20/200 in either eye
• People who are able to apply the study eye drops themselves, or who have a caregiver available to apply all doses for them

Who may not be able to join:

• People with a known allergy or sensitivity to bromfenac, nepafenac, diclofenac, or any ingredient in the study treatment, including numbing drops, dilating drops, or fluorescein dye
• People who have inflammation inside the eye being studied, detected at the screening visit
• People with certain blood disorders, bone marrow problems, uncontrolled stomach ulcers, inflammatory bowel disease, ulcerative colitis, or uncontrolled/unstable lung, heart, blood vessel, autoimmune, liver, kidney, or nervous system conditions
• People who have used certain anti-inflammatory medications (NSAIDs) or specific eye or body medications (gentamicin or cyclosporine eye drops) within 7 days before the study starts or during the study — though low-dose aspirin (81 mg or less per day) on a stable dose is allowed
• People who have diabetes of any type
• People who have any problems at the back of the eye where the vitreous meets the retina, as seen on a special eye scan
• People who have previously had a specific type of eye surgery (pars plana vitrectomy) in the eye being studied
• People with certain types of glaucoma, including any secondary glaucoma, closed-angle glaucoma, or severe open-angle glaucoma
• People who have used certain eye pressure-lowering drops called prostaglandins within 30 days before the study starts or during the study
• People who have active corneal (front of the eye) problems in the study eye at the screening visit, including a specific condition called superficial punctate keratitis
• People who have any inflammation around or inside the study eye at the screening visit — mild eyelid inflammation (blepharitis) may be acceptable, but not if combined with conjunctivitis or eyelid swelling/redness; people with ongoing, unresolved uveitis are also not eligible
• People who have used steroid medications — in any form including eye drops, inhaled, or tablets — within 14 days before the screening visit
• People with a history of alcohol or drug misuse within the 6 months before the screening visit
• People who are pregnant or currently breastfeeding
• People who have taken part in another clinical trial of an investigational drug or device within 30 days before being enrolled in this study

Important: Always verify eligibility with the trial site directly before applying.